Stathmin 2 is a potential treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis.

MLA

Liu, Yunqing, et al. “Stathmin 2 Is a Potential Treatment Target for TDP-43 Proteinopathy in Amyotrophic Lateral Sclerosis.” Translational Neurodegeneration, vol. 13, no. 1, Apr. 2024, pp. 1–4. EBSCOhost, https://doi.org/10.1186/s40035-024-00413-0.

APA

Liu, Y., Yan, D., Yang, L., Chen, X., Hu, C., & Chen, M. (2024). Stathmin 2 is a potential treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis. Translational Neurodegeneration, 13(1), 1–4. https://doi.org/10.1186/s40035-024-00413-0

Chicago

Liu, Yunqing, Dejun Yan, Lin Yang, Xian Chen, Chun Hu, and Meilan Chen. 2024. “Stathmin 2 Is a Potential Treatment Target for TDP-43 Proteinopathy in Amyotrophic Lateral Sclerosis.” Translational Neurodegeneration 13 (1): 1–4. doi:10.1186/s40035-024-00413-0.